U.S., March 6 -- ClinicalTrials.gov registry received information related to the study (NCT07451054) titled 'CD45BE-HSPC + CART-45 Cells' on Feb. 27.
Brief Summary: This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
Study Start Date: April, 2026
Study Type: INTERVENTIONAL
Condition:
B-Cell Non-Hodgkin Lymphoma (NHL)
Richter's Transformation
T-Cell Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Interve...